Fomivirsen

Fomivirsen
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
Pregnancy
category
Routes of
administration		 Intravitreal injection
ATC code S01AD08 (WHO)
Identifiers
CAS Number 160369-77-7 YesY
ChemSpider none
KEGG D02736 YesY
ChEMBL CHEMBL1201688 N
Chemical and physical data
Formula C204H263N63O114P20S20
Molar mass 6682.4 g/mol
 NYesY (what is this?)  (verify)

Fomivirsen (brand name Vitravene) is an antiviral drug. It is used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS. It was licensed by the FDA for CMV in Aug 1998.

It is a synthetic 21 member oligonucleotide with phosphorothioate linkages (which are resistant to degradation by nucleases) and has the sequence:

Mechanism

It is an oligonucleotide[1] that blocks translation of viral mRNA by binding to the complementary sequence of the mRNA transcribed from the template segment of a key CMV gene UL123, which encodes the CMV protein IE2. It was the first antisense antiviral approved by the FDA.[2]

Administration

It is available as an intraocular injection in a concentration of 6.6 mg/mL (CMV commonly manifests as chorioretinitis).[3]

See also

References

  1. ↑ Mulamba GB, Hu A, Azad RF, Anderson KP, Coen DM (April 1998). "Human Cytomegalovirus Mutant with Sequence-Dependent Resistance to the Phosphorothioate Oligonucleotide Fomivirsen (ISIS 2922)". Antimicrob. Agents Chemother. 42 (4): 971–3. PMC 105584Freely accessible. PMID 9559825.
  2. ↑ Roush W (May 1997). "Antisense aims for a renaissance". Science. 276 (5316): 1192–3. doi:10.1126/science.276.5316.1192. PMID 9182327.
  3. ↑ Katzung, Bertram G. (2006). Basic and Clinical Pharmacology (10th ed.). New York: McGraw-Hill Medical Publishing Division. p. 817. ISBN 0-07-145153-6.

Further reading

  • Grillone, LR; Lanz, R (2001). "Fomivirsen". Drugs Today (Barc). 37 (4): 245–255. PMID 12768225. 
  • Geary R, Henry S, Grillone L (2002). "Fomivirsen: clinical pharmacology and potential drug interactions". Clin Pharmacokinet. 41 (4): 255–60. doi:10.2165/00003088-200241040-00002. PMID 11978144. 
  • Vitravene Study, Group (2002). "Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS". Am J Ophthalmol. 133 (4): 475–83. doi:10.1016/S0002-9394(02)01326-0. PMID 11931781. 
  • Roehr B (1998). "Fomivirsen approved for CMV retinitis". J Int Assoc Physicians AIDS Care. 4 (10): 14–6. PMID 11365956. 


This article is issued from Wikipedia - version of the 9/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.